Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks
The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Abstract
ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTIrreversible Protein Kinase Inhibitors: Balancing the Benefits and RisksTjeerd Barf* and Allard KapteinView Author Information Drug Discovery Unit, Covalution Pharma BV, Ravenstein, The Netherlands*Phone: +31 618 193139. E-mail, [email protected]Cite this: J. Med. Chem. 2012, 55, 14, 6243–6262Publication Date (Web):May 23, 2012Publication History Received7 March 2012Published online8 June 2012Published inissue 26 July 2012https://pubs.acs.org/doi/10.1021/jm3003203https://doi.org/10.1021/jm3003203review-articleACS PublicationsCopyright © 2012 American Chemical SocietyRequest reuse permissionsArticle Views13870Altmetric-Citations266LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Inhibition,Inhibitors,Kinase inhibitors,Monomers,Peptides and proteins Get e-Alerts
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the 1970s, researchers reported that covalent drugs produce hepatotoxicity resulting from off-target effects via unselectively modifying non-target proteins with their highly reactive groups [37, 45].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [45]
Citations
Cites
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Fibroblast growth factors, their receptors and signaling
Powers, C. J., McLeskey, S. W., & Wellstein, A. (2000) · Endocrine-related cancer · doi:10.1677/erc.0.0070165 · Cited by 1,332
Research works printed but not linked: 5
- Powis G., 1994, Cancer Res., 54, 2419
- Wood E. R., 2008, Proc. Natl. Acad. Sci. U.S.A., 105, 2772
- Brigdes A. J., 2000, Chem. Rev., 101, 2541
- Advani, R.; Sharman, J.; Smith, S.; Boyd, T.; Grant, B.; Kolibaba, K.; Furman, R.; Buggy, J.; Loury, D.; Hedrick, E.; Izumi, R.; Hamdy, A.; Fowler, N.The Btk Inhibitor PCI-32765 Is Highly Active and Well Tolerated in Patients with Relapsed/Refractory B Cell Malignancies: Final Results from a Phase I Study. Presented at the 11th International Conference on Malignant Lymphoma (ICML), Lugano, Switzerland, June 15–18, 2011.
- Petter, R.Targeted Covalent Kinase Inhibitors: AVL 292 as a Potent, Irreversible and Selective Inhibitor of Btk. Presented at the 5th Anglo-Swedish Medicinal Chemistry Symposium (ASMC), Åre, Sweden, March 20–23, 2011.
Cited by
Items 301–386 of 386
Allosteric regulation of BTK by the PHTH domain and small molecules
Amatya, N. (2021) · Iowa State University Digital Repository (Iowa State University) · doi:10.31274/etd-20210609-5
Antineoplastic and Immunomodulating Agents (L)
Kleemann, A. (2022) · Ullmann's Encyclopedia of Industrial Chemistry · doi:10.1002/14356007.a05_001.pub4
Pitts, W. J., & Dyckman, A. J. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc203.pub2
Occhipinti, M. A., Ferrara, R., Imbimbo, M., Simeon, V., Fiscon, G., Marchal, C., Skoetz, N., & Viscardi, G. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015140
Development of the First Covalent Monopolar Spindle Kinase 1 (MPS1/TTK) InhibitorPreprint
Serafim, R. A. M., Santiago, A. D. S., dos Reis, C., Takarada, J. E., Mezzomo, P., Massirer, K. B., Schwalm, M. P., Kudolo, M., Gerstenecker, S., Chaikuad, A., et al. (2021) · ChemRxiv · doi:10.26434/chemrxiv.14601264
Erdogan, F., Chowdhury, R., Beldar, S., Chandy, T. B., Allan, R. G., de Araujo, E. D., & Gunning, P. T. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-hfntq
Development of Highly Potent and Selective FGFR4 Inhibitors Based on SNAr ElectrophilesPreprint
Schwarz, M., Kurkunov, M., Wittlinger, F., Rudalska, R., Wang, G., Schwalm, M. P., Rasch, A., Wagner, B., Laufer, S., Knapp, S., et al. (2024) · ChemRxiv · doi:10.26434/chemrxiv-2024-n89hr
Aljoundi, A. (2021) · ResearchSpace (University of KwaZulu-Natal) · doi:10.29086/10413/22663
Fan, D., Dong, H., Li, A., Zhang, Y., Wang, S., Tu, Y., & Wang, L. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673305941240605050450
An Overview of Protein Kinase Inhibitors
De, S. K. (2024) · Springer eBooks · doi:10.1007/978-3-031-75682-5_1
Targeted protein kinase inhibitor imatinib
Peng, L., & Ding, K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27402-2.00010-3
A case study of the irreversible covalent epidermal growth factor receptor (EGFR) inhibitor—afatinib
Yu, Y., & Chen, W. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27402-2.00005-x
Kinase Inhibitors and Computer-Aided Drug Design Methods
Pedreira, J. G. B., & Pinheiro, P. D. S. M. (2024) · Computer-aided drug discovery and design · doi:10.1007/978-3-031-76718-0_18 · Cited by 1
On‐Membrane Supramolecular Assemblies Serving as Bioorthogonal Gating for Melphalan
Xu, H., Yao, Q., Hu, X., Zheng, D., Ren, C., Ren, Z., & Gao, Y. (2025) · Angewandte Chemie · doi:10.1002/ange.202502922
Mao, B., Zhang, Y., Wang, Y., You, Q., & Guo, X. (2025) · Scientia Sinica Chimica · doi:10.1360/ssc-2025-0121
Thermodynamics and mechanism of afatinib–EGFR binding through a QM/MM approach
Kisku, A., Wahi, R., & Mishra, R. K. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00354g
Molecular Dynamics-Guided Design and Chemoproteomic Profiling of Covalent Kinase Activity ProbesPreprint
Chakraborty, P., Carlos, A. J., Thomas, T., Ghaby, K., Fathi, S., Sharma, M., Nguyen, N. K., Farmwald, M., Blachowicz, L., Yu, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.17.683178
Zhang, B., Zhang, B., Xiong, H., Zhou, J., Wang, M., Tian, B., & Nan, J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36518-8.00023-0
Development of small molecules modulating the activity of the nucleoside kinase dCK
Yaala, K. B. (2021) · theses.fr (ABES) · doi:10.70675/749d80bcze0abz4780za87czd786c1617d69
A Hetero-multivalent Covalent Strategy for Enhanced Pulmonary Fibrosis TherapyPreprint
Ge, G., Zhu, G., Deng, Y., Wu, H., Zhang, H., Zhu, G., Zeng, H., Li, N., Wang, L., Fan, Y., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9244913/v1
Bagde, P. H., Deb, B., Shrivastava, H., & Jha, H. C. (2026) · Springer eBooks · doi:10.1007/978-981-95-9777-2_13
Riding toward Selectivity: Optimization of Covalent 7-Azaindole-Based BMX Kinase Inhibitors
Liang, X. J., Albertini, C., Kronenberger, T., Shevchenko, E., Rasch, A., Berger, B., Schwalm, M. P., Berger, L. M., Krämer, A., Serafim, R. A. M., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01366
Three Thiol-Reactive Reagents drive Synergistic Lethality in Glioblastoma cellsPreprint
Kashi, O. Y., Cohen, A., Earhart, K., Elliot, J. D., Denise, M. R., Rauniyar, S., Qureshi, G., Umschweif, G., Evan, K. N., & Atlas, D. (2026) · Research Square · doi:10.21203/rs.3.rs-9978519/v1
Bravo, E., Pastrana, C. C., Lamkin, E. N., Ciurko, K., & Taylor, J. (2026) · Cells · doi:10.3390/cells15151383
Dahab, M. A., Ashoub, A. F., Ali, R. A., Sallam, A. S., & Mayhoub, A. S. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119449
BindingDB (2025) · UC San Diego · doi:10.7270/q2vm4hvh
BindingDB Entry 50018469: Activity-based protein profiling: Recent advances in medicinal chemistry.
BindingDB (2024) · UC San Diego · doi:10.7270/q23b64bd
BindingDB (2020) · UC San Diego · doi:10.7270/q25x2cjz
BindingDB (2016) · UC San Diego · doi:10.7270/q2fn1513
BindingDB (2022) · UC San Diego · doi:10.7270/q2736vnz
BindingDB (2019) · UC San Diego · doi:10.7270/q2c53p3h
BindingDB Entry 50012746: Discovery of quinoline-based irreversible BTK inhibitors.
BindingDB (2022) · UC San Diego · doi:10.7270/q2tb1bm3
BindingDB Entry 50047333: Recent progress on third generation covalent EGFR inhibitors.
BindingDB (2017) · UC San Diego · doi:10.7270/q2c24z9v
BindingDB Entry 50014256: A sulfonyl fluoride derivative inhibits EGFR
BindingDB (2022) · UC San Diego · doi:10.7270/q2sq946r
BindingDB (2016) · UC San Diego · doi:10.7270/q2sq9207
BindingDB (2023) · UC San Diego · doi:10.7270/q2t157jc
BindingDB (2017) · UC San Diego · doi:10.7270/q2ks6tdd
BindingDB Entry 50048252: Non-kinase targets of protein kinase inhibitors.
BindingDB (2018) · UC San Diego · doi:10.7270/q2125vnc
BindingDB (2022) · UC San Diego · doi:10.7270/q2rv0sch
BindingDB (2019) · UC San Diego · doi:10.7270/q2gh9m74
BindingDB Entry 50002046: Small molecule inhibitors of anthrax edema factor.
BindingDB (2020) · UC San Diego · doi:10.7270/q25d8vd2
Metadata
- Authors
- Barf, T., & Kaptein, A.
- Affiliations
- Drug Discovery Unit, Covalution Pharma BV, Ravenstein, The Netherlands
- Corresponding author
- Barf, Tjeerd
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2012-06-08
- Volume
- 55
- Issue
- 14
- Pages
- 6243-6262
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2057079741
- Cited by
- 331
- References
- 108
- Citations by year
- 2026: 14 · 2025: 16 · 2024: 21 · 2023: 17 · 2022: 9 · 2021: 30 · 2020: 38 · 2019: 26 · 2018: 22 · 2017: 38 · 2016: 32 · 2015: 22 · 2014: 25 · 2013: 14 · 2012: 7
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- kinase inhibitors, covalent inhibitors, drug development, benefits and risks, kinase-targeted therapy
- MeSH terms
- Animals, Cell Line, Humans, Protein Kinases, Risk, Structure-Activity Relationship, Time Factors, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.